You have 9 free searches left this month | for more free features.

CD30, r/r NHL, DLBCL, ALCL, ENKTCL, PMBCL, PTCL, adult

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Secondary CNS Lymphoma Trial in Beijing (Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab)

Recruiting
  • Secondary Central Nervous System Lymphoma
  • Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
May 25, 2022

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory DLBCL Trial in Spain, United Kingdom, United States

Completed
  • Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Marietta, Georgia
  • +27 more
Feb 4, 2022

Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos Trial in Shanghai (Zanubrutinib, Tislelizumab)

Recruiting
  • Primary Mediastinal Large B Cell Lymphoma
  • EBV-Positive DLBCL, Nos
  • Shanghai, Shanghai, China
    Ruijin Hospital
Mar 29, 2021

Molecular Classification of Relapsed/Refractory Diffuse Large

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Gene Expression Profiling
  • Gene expression profile
  • Shanghai, Shanghai, China
    Yian Zhang
Mar 31, 2022

Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing

Recruiting
  • Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
  • Decitabine-primed Tandem CD19/CD20 CAR T Cells
  • Decitabine-primed Tandem CAR19/20 engineered T cells
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Mar 24, 2022

Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Idasanutlin, Obinutuzumab, Venetoclax)

Terminated
  • Follicular Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Aurora, Colorado
  • +20 more
Dec 5, 2021

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (Ociperlimab, Tislelizumab,

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 4, 2022

DLBCL Trial in Shanghai (IBI110 plus sintilimab, IBI110)

Not yet recruiting
  • DLBCL
  • Shanghai, Shanghai, China
    Ruijin Hospital affiliated to Shanghai Jiao Tong University Scho
Sep 1, 2021

Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL) Trial in Tianjin (Ex-vivo expanded allogeneic ?dT cells)

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • Peripheral T Cell Lymphoma (PTCL)
  • Ex-vivo expanded allogeneic γδT cells
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Disease Hospital
Jan 5, 2021

Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab, Polatuzumab vedotin, Tocilizumab)

Recruiting
  • Non-Hodgkin Lymphoma
  • Buenos Aires, Argentina
  • +18 more
Aug 10, 2022

Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Apr 24, 2022

Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

Completed
  • Marginal Zone Lymphoma
  • +2 more
  • Harbin, Heilongjiang, China
  • +3 more
Oct 26, 2021

NHL, Leukemia Trial in Australia (ETH-155008)

Recruiting
  • NHL
  • Leukemia
  • Adelaide, South Australia, Australia
  • +4 more
Jun 8, 2022

Diffuse Large B Cell Lymphoma Trial in Busan (PrednisoLONE 50 MG)

Completed
  • Diffuse Large B Cell Lymphoma
  • PrednisoLONE 50 MG
  • Busan, Sue-gu, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Relapsed Diffuse Large B-cell Lymphoma, Refractory DLBCL Trial in Worldwide (Polatuzumab Vedotin, Mabthera, Ifosfamide)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +4 more
  • Graz, Austria
  • +62 more
Aug 2, 2022

DLBCL, Transformed Follicular Lymphoma to DLBCL, Transformed Marginal Zone Lymphoma to DLBCL Trial in Columbus

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Diffuse B-Cell Lymphoma Trial in Worldwide (Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion)

Completed
  • Diffuse B-Cell Lymphoma
  • Avadomide (CC-122)
  • +4 more
  • Washington, District of Columbia
  • +14 more
Apr 28, 2021

B-cell Malignancy Trial in Xuzhou (ThisCART22 cells)

Recruiting
  • B-cell Malignancy
  • ThisCART22 cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Nov 9, 2021

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 4, 2022

Lymphoma Trial in China (Obinutuzumab, Glofitamab, Tocilizumab)

Recruiting
  • Lymphoma
  • Beijing, China
  • +6 more
Aug 4, 2022

Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Worldwide (Mosunetuzumab SC, Tiragolumab, Atezolizumab)

Recruiting
  • Non-Hodgkin Lymphoma, Follicular Lymphoma
  • Mosunetuzumab SC
  • +3 more
  • Ann Arbor, Michigan
  • +14 more
Aug 12, 2022

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma

Completed
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • CAR-T
  • Allo-HSCT cohort
  • East Hanover, New Jersey
    Novartis Investigative Site
Jun 29, 2022

B-cell Malignancy Trial in Xuzhou (ThisCART19 cells)

Recruiting
  • B-cell Malignancy
  • ThisCART19 cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Oct 25, 2021

DLBCL Trial in Cleveland (ME-401, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Feb 2, 2022

B-cell Non-Hodgkin's Lymphoma Trial in Shanghai (Human CD19Targeted T Cells Injection)

Recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Human CD19Targeted T Cells Injection
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jun 29, 2022